Pooled analysis of objective cough frequency in participants with chronic cough treated with gefapixant in two Phase 3 clinical trials (COUGH-1 AND COUGH-2)

Friday, February 11th, 2022

This pooled analysis examined the effect of gefapixant versus placebo on objective cough frequency in 2044 adult patients with refractory or unexplained chronic cough enrolled in the Phase 3 COUGH-1 and COUGH-2 trials. Objective cough frequency was measured using the Vitalograph VitaloJAK recording device.

Author Smith JA et al.

Publication Thorax

Year 2021

Device Type VitaloJAK

April 8, 2024

Prediction model derived from large-scale proteomics for risk of chronic obstructive pulmonary disease in the general population

April 8, 2024

Prevalence, characteristics and significant predictors for cardiovascular disease of patients with preserved ratio impaired spirometry: A 10-year prospective cohort study in China

April 8, 2024

Morphine for treatment of cough in idiopathic pulmonary fibrosis (PACIFY COUGH): A prospective, multicentre, randomised, double-blind, placebo-controlled, two-way crossover trial

April 8, 2024

Tomo-PIV in a patient-specific model of human nasal cavities: A methodological approach

April 8, 2024

Association of systemic anticholinergic medication use and accelerated decrease in lung function in older adults

View All Articles

Pooled analysis of objective cough frequency in participants with chronic cough treated with gefapixant in two Phase 3 clinical trials (COUGH-1 AND COUGH-2)

Quality

Join Our Team

Legal